Recent SEC filings detail the company’s advancement of IKT-001 into a pivotal Phase 3 trial and completion of a significant public offering to support clinical development.

• In November 2025, Inhibikase announced plans to advance IKT-001 to a global pivotal Phase 3 clinical study in Pulmonary Arterial Hypertension, adopting a two-part adaptive study design named IMPROVE-PAH [S1].
• The Phase 3 study design includes Part A with 140 patients focusing on pulmonary vascular resistance at Week 24, and Part B with 346 patients focusing on 6-minute walk distance at Week 24 [S1].
• The company completed a public offering in late 2025, raising approximately $93.6 million in net proceeds to fund clinical development activities [S1].
• As of December 31, 2025, the company reported cash and cash equivalents of $178.8 million and short-term investments of $39.5 million, with a current ratio of 21.7 and cash ratio of 26.3, indicating strong liquidity [S1].
• The company reported a net loss of $48.3 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$0.49 [S1].
• The Board of Directors maintains active oversight of risk management including cybersecurity, with no history of breaches and ongoing monthly system audits [S1].
• The company is not currently involved in any material litigation or legal proceedings [S1].

The company’s advancement of IKT-001 into a global pivotal Phase 3 trial with an adaptive design reflects a strategic approach to clinical development that could streamline regulatory pathways. Strong liquidity from recent capital raises provides financial flexibility to support these efforts. Effective board oversight of risk management and cybersecurity adds operational resilience. If clinical results demonstrate efficacy and safety, the company could establish a foundation for future commercialization and growth.

As a clinical-stage biopharmaceutical company, Inhibikase faces significant risks including clinical trial execution, regulatory approval uncertainties, and the absence of current product revenues. The reported net losses and ongoing cash burn highlight the need for continued capital access. The company’s reliance on a single lead candidate increases vulnerability to clinical or regulatory setbacks. Additionally, the lack of detailed public disclosure on broader business operations and product pipeline limits external visibility into its long-term sustainability.

Inhibikase Therapeutics operates in the specialized field of clinical-stage biopharmaceutical development, focusing on novel treatments for pulmonary arterial hypertension and neurological diseases. Its moat is primarily based on its proprietary drug candidate IKT-001 and its progression into pivotal clinical trials, which may provide regulatory exclusivity and potential market differentiation if approved. The company’s strong liquidity position supports ongoing clinical development activities. However, as a clinical-stage company without commercial products or revenues, its competitive advantage depends heavily on successful clinical outcomes and regulatory approvals.

• Clinical Development Risk: The success of the company depends on the outcomes of its pivotal Phase 3 trial for IKT-001 in PAH, which carries inherent uncertainties related to efficacy, safety, and regulatory approval.
• Financial Risk: The company reported a net loss of $48.3 million for the fiscal year ended 2025 and relies on capital raises to fund operations, which may dilute existing shareholders and impact financial stability.
• Operational Risk: Execution of complex clinical trials and maintaining regulatory compliance require effective management and resources; any delays or failures could adversely affect the company.
• Cybersecurity Risk: Although the company has not experienced breaches, cybersecurity remains a risk area requiring ongoing management and oversight by the Board and external IT teams.
• Legal Risk: While not currently involved in material litigation, potential future legal proceedings could result in financial and operational impacts.

• Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing drug candidates for neurological and pulmonary diseases as indicated by its clinical trial activities.
• The company plans to advance its lead drug candidate IKT-001 to a global pivotal Phase 3 clinical trial in Pulmonary Arterial Hypertension (PAH), named IMPROVE-PAH, with a two-part adaptive study design.
• The Phase 3 study design includes Part A as a double-blind, placebo-controlled study in 140 patients with a primary endpoint of pulmonary vascular resistance (PVR) at Week 24, and Part B with 346 patients focusing on 6-minute walk distance (6MWD) at Week 24.
• The company has recently completed a public offering raising approximately $93.6 million net proceeds, with potential for additional proceeds if underwriters exercise their option in full.
• As of December 31, 2025, the company reported cash and cash equivalents of $178.8 million and short-term investments of approximately $39.5 million, with current assets totaling about $180.1 million and current liabilities of $8.3 million, resulting in a strong current ratio of 21.7 and cash ratio of 26.3.
• The company reported a net loss of $48.3 million for the fiscal year ended December 31, 2025, with basic and diluted earnings per share of -$0.49.
• The Board of Directors maintains oversight of risk management including cybersecurity risks, with management and an external IT team responsible for strategy and risk communication. The company has not experienced any cybersecurity breaches and conducts monthly system audits.
• The company is not currently involved in any material litigation or legal proceedings.
• The company terminated its ATM Prospectus and related sales agreement in November 2025 and has not made any sales under that agreement.
• The company’s CEO is Mark Iwicki, who is involved in risk management and corporate leadership.